Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2026 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. ( MRVI ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Debra Hart - Senior Director of Investor Relations Bernd Brust - CEO & Director Rajesh Asarpota - EVP &…
What Maravai LifeSciences (MRVI) Said on Its Q3 Earnings Call
Maravai LifeSciences NASDAQ: MRVI raised its 2026 revenue and adjusted EBITDA forecasts after reporting third-quarter sales growth of 10%, driven by demand for mRNA products and continued growth at its Cygnus business.…
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.…
● Business WireNov 4, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Maravai LifeSciences Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results fo…
● Business WireOct 14, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter financia…
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Has Average Price Target of $6.83
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) has received an average recommendation of "Hold" from the five ratings firms that are covering the stock, Marketbeat reports. One investment analyst ha…
TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new pate…
Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel
Maravai (MRVI) is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, embedding products across the customer lifecycle. Q2 2026 marked a profitability inflection, with gross margins ri…
Article counts from the last market-wide feed page, across every symbol we track and not just MRVI · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.